Fig. 3

Correlative studies on patient plasma. Symbol and lines graph representing the concentration of IL-6 at C1D1 and C1D5 (a) or at C1D1 and C2D1 (b) according to the decrease or increase in tumour size after the first scan (n = 16). c Dot plot of IL-6 concentration in plasma of C2D1 patients according to RECIST response (CR complete response, PR partial response, SD stable disease, PD progression disease) (n = 16). n.s. not significant, *p < 0.05; comparison using Mann–Whitney unpaired test. d Dot plot of delta IL-6 concentration between C1D1 and C2D1 according to RECIST response (CR complete response, PR partial response, SD stable disease, PD progression disease) (n = 16). n.s. not significant, *p < 0.05; comparison using Mann–Whitney unpaired test. e Kaplan–Meier curves for progression-free survival with patients stratified according to the positive or negative delta of IL-6 concentration between C1D1 and C2D1. Two-sided P value with significance level set at 0.05. f, g Patient plasma was recovered at C1D1, C1D2 and C3D1 and cytokine and chemokine secretion was analysed by bioplex. Volcano plot describing differential analysis performed on bioplex data between C1D1 and C1D2 (f) and C1D1 and C3D1 (g) timepoints. The log2 FC indicates the mean expression level for each gene. Each dot represents one analysed target. h–r Patient plasma was recovered at C1D1, C1D2 and C3D1 and cytokine and chemokine secretion was analysed by bioplex. Box and whisker plots showing the concentration of Eotaxin (h), CCL2 (i), CXCL2 (j), CCL4 (k), CD40-L (l), Flt3-L (m), soluble Granzyme B (n), soluble PD-L1 (o), IL-13 (p), CXCL1 (q) and CCL5 (r) in patient plasma. n.s. not significant, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001; comparison using Wilcoxon matched-pairs test. Survival distributions were compared using the log-rank test (e)